Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Health Tidings

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Health Tidings

1,301 stories · every one Fact-Checked
KaliVir's VET3-TGI oncolytic immunotherapy demonstrates a 71% response rate in advanced cutaneous cancers in the STEALTH-001 trial.Health TidingsKaliVir Reports 71% Response Rate With VET3-TGI in Skin CancersKaliVir Immunotherapeutics has reported a 71% objective response rate with investigational oncolytic immunotherapy VET3-TGI in patients with advanced cutaneous malignancies who progressed following anti-PD-1/PD-L1 treatment.9 Nov 2026 · 5 min read
Fact-Checked
Onchilles Pharma N17350 investigational cancer therapy showing potential immune response against non-injected tumour lesions.Health TidingsOnchilles Pharma Advances in Situ Cancer Vaccine Strategy with N17350Onchilles Pharma has reported preliminary Phase 1/2 findings for N17350, with five non-injected tumour lesions becoming undetectable in one patient with Merkel cell carcinoma.6 Nov 2026 · 4 min read
Fact-Checked
OncoC4's investigational PD-1/VEGF bispecific antibody cesalatamig showing antitumor activity in previously treated non-small cell lung cancer.Health TidingsOncoC4 Reports 33% Response Rate with Cesalatamig in NSCLCOncoC4 reported a 33% objective response rate and 90% disease control rate with its investigational PD-1/VEGF bispecific antibody cesalatamig at 10 mg/kg in previously treated PD-(L)1-resistant or refractory…6 Nov 2026 · 4 min read
Fact-Checked
Lilly_OFG_Bottle_Tablet_G1_BottleOnly_v03Health TidingsLilly Expands Zepbound and Foundayo Access Through Hims & HersEli Lilly has partnered with Hims & Hers Health to expand access to its FDA-approved obesity medicines, Zepbound and Foundayo, through the telehealth platform.6 Nov 2026 · 3 min read
Fact-Checked
Edgewise Therapeutics EDG-7500 Phase 3 development for obstructive and nonobstructive hypertrophic cardiomyopathy.Health TidingsEdgewise Submits EDG-7500 Phase 3 Protocol After FDA MeetingEdgewise Therapeutics has submitted the Phase 3 STRATUS-HCM protocol for EDG-7500 following a productive FDA End-of-Phase 2 meeting.6 Nov 2026 · 4 min read
Fact-Checked
Chai Discovery and Roche collaboration to apply AI-powered protein design technology across drug discovery programs.Health TidingsChai Adds Roche to Its Expanding AI Drug Discovery NetworkChai Discovery has partnered with Roche to apply its AI-powered protein design models across multiple drug discovery programs.6 Nov 2026 · 3 min read
Fact-Checked
Resolution Therapeutics RTX001 engineered macrophage therapy targeting inflammation and fibrosis in end-stage liver disease.Health TidingsResolution Reports 42% Lower Clinical Event Risk in ESLD, Advances RTX001 Towards US Pivotal TrialResolution Therapeutics reported a 42% relative reduction in composite clinical events with RTX001 in the six-month interim analysis of its Phase I/II EMERALD trial.6 Nov 2026 · 4 min read
Fact-Checked
Precision BioSciences PBGENE-DMD gene-editing therapy targeting the dystrophin gene in Duchenne muscular dystrophy.Health TidingsPrecision Wins DSMB Support to Expand PBGENE-DMD TrialPrecision BioSciences has received a positive DSMB safety review for PBGENE-DMD, supporting additional patient dosing and completion of Part 1 enrollment in the Phase 1/2 FUNCTION-DMD study.5 Nov 2026 · 4 min read
Fact-Checked
Boehringer Ingelheim and Sino Biopharmaceutical oncology partnership covering antibody-drug conjugate and T-cell engager programs.Mergers & AcquisitionsBoehringer Ingelheim and China’s Sino Strike $7.4B Oncology DealBoehringer Ingelheim has secured options on six preclinical oncology programs from Sino Biopharmaceutical, expanding its ADC and T-cell engager pipeline through an agreement featuring US$358 million in upfront…5 Nov 2026 · 4 min read
Fact-Checked
Cenobamate XCOPRI medication box and tablets for epilepsy treatmentHealth TidingsSK Submits sNDA for Cenobamate (XCOPRI) in PGTCSK Biopharmaceuticals submits FDA sNDA for cenobamate (XCOPRI) in PGTC seizures based on Phase 3 trial data showing a 71.9% seizure reduction.5 Nov 2026 · 3 min read
Fact-Checked
HUTCHMED sovleplenib FDA orphan drug designation for autoimmune hemolytic anemiaHealth TidingsHUTCHMED Gains Second FDA Orphan Status for Sovleplenib in AIHAHUTCHMED has received its second FDA Orphan Drug Designation for sovleplenib, this time for autoimmune hemolytic anemia (AIHA).5 Nov 2026 · 3 min read
Fact-Checked
Evommune EVO570 oral VAV1 molecular glue degrader licensed from Hinova Pharmaceuticals for autoimmune disease development.Mergers & AcquisitionsEvommune Bets on EVO570 and VAV1 Degradation with $1.1B Hinova DealEvommune has secured worldwide rights outside Greater China to Hinova’s investigational oral VAV1 molecular glue degrader EVO570 in a deal worth up to $1.1 billion.5 Nov 2026 · 4 min read
Fact-Checked
Page 3 of 109